STM publisher Springer, Germany, has announced that it will publish Neurotherapeutics, the official journal of the American Society for Experimental NeuroTherapeutics (ASENT), beginning in 2011. With the switch to Springer, the journal will change its format of publishing review articles only to offering original research articles as well. The journal's editor-in-chief is Dr. Alan Faden, who directs the Shock Trauma and Anesthesiology Research (STAR) Center at the University of Maryland School of Medicine.
Throughout its six-year history, Neurotherapeutics has exclusively published critical reviews in thematic, quarterly issues that highlight neurotherapeutics related to the clinical neurosciences. Each issue is developed by one or more distinguished guest editors who are expert in the topic area. The journal achieved a debut Impact Factor of 5.38 in 2009, placing it in the top quartile of journals in both the Neurosciences and Pharmacology & Pharmacy categories.
Springer will create a Neurotherapeutics portal and a page on the NeuroNetwork to promote themed issues, facilitate communication among the journal's readers, promote society news, and highlight both the preclinical and clinical articles in the journal through RSS feeds and podcasts. All back issues will be available on Springer's online platform SpringerLink. The journal will take advantage of the online submission system Editorial Manager and all articles will publish in the Online First format on SpringerLink ahead of print publication. In addition, all content from the journal will be provided to PubMed Central and available to the public twelve months after print publication.
Search for more Neuroscience related books/journals
